Expert Q&As
FRENCH MARKET - Q&A 6
What is the "Exploitant" status and why is it essential for pharmaceutical companies entering the French Market?
Access decades of experience
What’s Inside the Q&A:
Access Senior-Level Know-How
Learn from experts who have shaped real market-entry strategies and understand the subtleties behind compliance, operations, and execution in France.
France’s Hidden Power Roles
Meet the actors who silently govern authorization, promotion, safety, and oversight. Roles that rarely exist elsewhere but are decisive to launching successfully.
Dual Authority, One Product
Discover how legal responsibility and daily operations split between distinct leaders, and why multinational firms must adapt to a dual-authority model.
On-the-Ground Reality Check
Uncover what commercializing on French soil truly demands, from regulatory expectations to cross-functional decisions that can accelerate or block market access.
Download our expert answer
Discover our latest news
Expert Q&As
Launching in EU - Q&A 1
Why is launching a drug in Europe different from launching in the US?
Expert Q&As
Launching in EU - Q&A 3
How to choose the right location for our European headquarters or hub?
Expert Q&As
Launching in EU - Q&A 2
How should we go about hiring and building a European presence?
